CAMBRIDGE, Mass. May 23, 2023 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that it will be participating in the 2023 BIO...
– New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients – MARIPOSA Results Support Advancing AD109 to Phase 3 CAMBRIDGE, Mass. May 21, 2023 – Apnimed, a clinical-stage pharmaceutical company...
– New MARIPOSA Data Showing AD109 Had Statistically Significant Improvement in Both Objective and Subjective Outcomes to Be Featured as an Oral Presentation in the Breaking News in OSA: New Approaches and New Trials Mini Symposium – Data Supporting Use of Specific...
CAMBRIDGE, Mass. April 10, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
CAMBRIDGE, Mass. January 25, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
– Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA CAMBRIDGE, Mass. January 3, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment...
